Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia

• Published in: Nature communications Vol. 15; no. 1; p. 646
• Main Authors: Gurbatri, Candice R., Radford, Georgette A., Vrbanac, Laura, Im, Jongwon, Thomas, Elaine M., Coker, Courtney, Taylor, Samuel R., Jang, YoungUk, Sivan, Ayelet, Rhee, Kyu, Saleh, Anas A., Chien, Tiffany, Zandkarimi, Fereshteh, Lia, Ioana, Lannagan, Tamsin R. M., Wang, Tongtong, Wright, Josephine A., Kobayashi, Hiroki, Ng, Jia Q., Lawrence, Matt, Sammour, Tarik, Thomas, Michelle, Lewis, Mark, Papanicolas, Lito, Perry, Joanne, Fitzsimmons, Tracy, Kaazan, Patricia, Lim, Amanda, Stavropoulos, Alexandra M., Gouskos, Dion A., Marker, Julie, Ostroff, Cheri, Rogers, Geraint, Arpaia, Nicholas, Worthley, Daniel L., Woods, Susan L., Danino, Tal
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 20-01-2024; Nature Publishing Group; Nature Portfolio
• Subjects: 59; 59/5; 631/61/185; 631/67/1504/1885; 639/166/985; 692/4020/1503/1581; Adenoma; Adenoma - diagnosis; Adenoma - therapy; Animal models; Animals; Bioengineering; Clinical trials; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - diagnosis; Colorectal Neoplasms - genetics; Colorectal Neoplasms - therapy; CTLA-4 protein; Double-Blind Method; E coli; Engineers; Escherichia coli - genetics; Genetic engineering; Granulocyte-macrophage colony-stimulating factor; Health services; Humanities and Social Sciences; Humans; Mice; multidisciplinary; Nanobodies; Oral administration; Patients; PD-L1 protein; Probiotics; Prospective Studies; Salicylates; Salicylic acid; Science; Science (multidisciplinary); Tumors
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-024-44776-4

Bioengineered probiotics enable new opportunities to improve colorectal cancer (CRC) screening, prevention and treatment. Here, first, we demonstrate selective colonization of colorectal adenomas after oral delivery of probiotic
E. coli
Nissle 1917 (EcN) to a genetically-engineered murine model of CRC predisposition and orthotopic models of CRC. We next undertake an interventional, double-blind, dual-centre, prospective clinical trial, in which CRC patients take either placebo or EcN for two weeks prior to resection of neoplastic and adjacent normal colorectal tissue (ACTRN12619000210178). We detect enrichment of EcN in tumor samples over normal tissue from probiotic-treated patients (primary outcome of the trial). Next, we develop early CRC intervention strategies. To detect lesions, we engineer EcN to produce a small molecule, salicylate. Oral delivery of this strain results in increased levels of salicylate in the urine of adenoma-bearing mice, in comparison to healthy controls. To assess therapeutic potential, we engineer EcN to locally release a cytokine, GM-CSF, and blocking nanobodies against PD-L1 and CTLA-4 at the neoplastic site, and demonstrate that oral delivery of this strain reduces adenoma burden by ~50%. Together, these results support the use of EcN as an orally-deliverable platform to detect disease and treat CRC through the production of screening and therapeutic molecules.
There is an unmet medical need for the detection and treatment of early adenomas to prevent their progression to malignant disease. Here the authors show that orally administered E. coli Nissle 1917 can selectively colonize adenomas in mouse models and in patients as a detection tool, as well as deliver immunotherapeutics for colorectal neoplasia treatment.